The booster vaccination trial is still ongoing and further data will provide more information around safety and efficacy.
RYALTRIS is a fixed-dose combination therapy that provides relief for the symptoms of SAR, both nasal and ocular, in one easy-to-use nasal spray
Kokilaben Hospital is also the first hospital in Navi Mumbai to receive the SMART ICU certification
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.
Phase 2 study evaluating an investigational weekly oral combination treatment regimen of islatravir and Gilead Sciences’ lenacapavir to resume with lower dose of islatravir
Evusheld significantly reduced risk of severe COVID-19 or death in TACKLE Phase III treatment trial
If implemented across the world, it has the capability to save over 100,000 lives annually
He takes over leadership of Cell & Gene from Jean-Christophe Hyvert, enabling Jean-Christophe to increase his focus on his role as President of the Biologics Division
Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab
Subscribe To Our Newsletter & Stay Updated
